• Title of article

    Ipilimumab- and Nivolumab-Induced Colitis Causing SevereHypokalemia and QTc Prolongation

  • Author/Authors

    Anson, David University of Illinois College of Medicine Peoria - Peoria - IL, USA , Norton, Joseph Department of Internal Medicine - University of Illinois College of Medicine Peoria - Peoria - IL, USA , Chaucer, Benjamin Department of Internal Medicine - University of Illinois College of Medicine Peoria - Peoria - IL, USA , Bansal, Saurabh Department of Internal Medicine - University of Illinois College of Medicine Peoria - Peoria - IL, USA

  • Pages
    3
  • From page
    1
  • To page
    3
  • Abstract
    Immune-mediated colitis is an uncommon but well-documented adverse event in patients receiving nivolumab or ipilimumabtherapy. In this report, we present a 69-year-old man who developed severe hypokalemia and colitis with significant correctedQ-T segment (QTc) prolongation as a result of combination nivolumab-ipilimumab immunotherapy for clear cell renal cellcarcinoma.
  • Keywords
    Ipilimumab - , Nivolumab - , Induced Colitis Causing Severe Hypokalemia , QTc Prolongation , Immune-mediated colitis
  • Journal title
    Case Reports in Oncological Medicine
  • Serial Year
    2019
  • Full Text URL
    downloads.hindawi.com/journals/crionm/2019/7896749.pdf
  • Record number

    2610245

    • Link To Document
    https://search.isc.ac/dl/search/defaultta.aspx?DTC=10&DC=2610245